Cidara Therapeutics to Share Key Financial Insights Soon
Cidara Therapeutics Announces Upcoming Financial Results
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology firm based in San Diego, has exciting news for its stakeholders. The company is set to report its first quarter 2025 financial performance along with essential operational highlights. This announcement will come after the close of the U.S. financial markets on May 8, 2025.
Engaging with Investors
To keep investors and interested parties informed, Cidara will host a conference call and live webcast at 5:00 PM Eastern Time on the same day. This platform will allow the leadership team to discuss the financial results in detail and provide insights into the company's operational progress.
Conference Call Details
For those wishing to participate in this important conference call, here are the key details:
Date and Time
The conference call is scheduled for Thursday, May 8, 2025, at 5:00 PM Eastern Time.
How to Join the Call
Attendees can dial in using the following numbers:
- United States: 1-800-717-1738
- International: 1-646-307-1865
Make sure to have the conference ID ready, which is 90743, to ensure smooth access to the call.
About Cidara Therapeutics
Cidara Therapeutics is committed to harnessing its innovative Cloudbreak platform to advance the development of drug-Fc conjugates (DFCs). These DFCs are unique therapeutic agents consisting of targeted small molecules or peptides attached to a proprietary human antibody fragment. One of their flagship products, CD388, is a long-acting antiviral that aims for universal prevention of seasonal and pandemic influenza from a single dose by directly inhibiting viral replication.
Recent Developments
In recent months, Cidara achieved significant milestones. The FDA granted Fast Track Designation for CD388, highlighting its potential to address public health needs efficiently. Furthermore, the company successfully enrolled patients in Phase 2b clinical trials by December 2024, marking a significant step forward in the product development pipeline.
Expanding Horizons in Oncology
Cidara is not just focused on antiviral solutions; it is also venturing into oncology with additional DFCs in development. Recently, in July 2024, they received Investigational New Drug (IND) clearance for CBO421, which targets CD73 in solid tumors. This development represents Cidara's dedication to expanding the boundaries of treatment options available in the oncology landscape.
Contact Information
For further inquiries, Cidara has made available the following contacts:
Investor Relations
Brian Ritchie from LifeSci Advisors can be reached at (212) 915-2578 for more details on investor-related questions.
Media Relations
For media inquiries, Michael Fitzhugh from LifeSci Communications is available via email at mfitzhugh@lifescicomms.com.
Frequently Asked Questions
What is the main purpose of the upcoming conference call?
The conference call will discuss Cidara's financial results and provide updates on operational highlights.
When is the conference call scheduled?
The call is scheduled for May 8, 2025, at 5:00 PM Eastern Time.
How can investors participate in the call?
Investors can join the call by dialing the provided United States or International numbers along with the conference ID.
What are DFCs produced by Cidara Therapeutics?
Drug-Fc conjugates are innovative therapeutic agents designed by Cidara that combine targeting molecules with human antibody fragments.
What is the significance of CD388?
CD388 is a key product aimed at preventing influenza and has received Fast Track Designation by the FDA, highlighting its critical potential in public health.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
